In what may be seen as a positive development, it has emerged that the anti-estrogen drug Aromasin reduces the risk of breast cancer recurrence by about one-third in postmenopausal women previously treated with tamoxifen.
According to researchers, `Aromasin`, which has been approved by the FDA, obstructs the production of estrogen that is made outside of the ovaries.
The drug is also believed to prevent malignancies in women who have a risk due to age, family history and abnormal biopsy results.
Researchers claim that Aromasin reduces the risk of invasive breast cancer by 65% compared to a placebo.
Two other drugs, tamoxifen and raloxifene have also been approved by the FDA for cancer prevention though they have side effects like blood clots, strokes, leg cramps and joint pain.